Connect Biopharma Holdings Ltd(CNTB)Stock Analysis
AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →13F Pro Quality Score
Rank #2,575 of 2,961 stocks
Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Nov 14, 2026.
CNTB Stock Analysis & AI Quality Score
Data updated 2026-09-11AI stock analysis and institutional research for Connect Biopharma Holdings Ltd (CNTB), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores CNTB at 27.6/100 on a 32-signal composite quality model, placing it at rank #2,575 of 2,961 stocks — the bottom half of the AI-ranked universe. Based on the latest XBRL financial filings (Q2 2026), Connect Biopharma Holdings Ltd reports quarterly revenue of $2.8M, net income of $-17.3M, free cash flow of $-15.9M. Top institutional holders of CNTB by reported 13-F value include Ikarian Capital, 683 Capital Management, BOOTHBAY FUND MANAGEMENT, based on the most recent SEC filings. CNTB trades on the Nasdaq exchange and files with the SEC under CIK 1835268. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate CNTB daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Connect Biopharma Holdings Ltd directly from SEC EDGAR. Connect Biopharma Holdings Ltd's 13F Pro composite quality score has ranged between 12 and 29 since 2026, currently 27.6 — an improving long-term trajectory across 33 quarterly and live scoring snapshots.
Revenue
Q2 2026
$2.8M
Net Income
Q2 2026
$-17.3M
Free Cash Flow
Q2 2026
$-15.9M
Revenue & Net Income
Earnings Per Share
Key Financials Over Time
Export Financial Table · ProRevenue
-99.8% YoYNet Income
-255.0% YoYOperating Income
-158.7% YoYEPS (Diluted)
-257.1% YoYTotal Assets
-44.6% YoYOp. Cash Flow
-116.9% YoYFree Cash Flow
-112.0% YoY| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Revenue | $64.0K -99.8% | $26.0M | $0.00 | — | — | — |
| Net Income | $-55.5M -255.0% | $-15.6M +74.8% | $-62.1M | — | — | — |
| Operating Income | $-58.1M -158.7% | $-22.5M +67.5% | $-69.1M | — | — | — |
| EPS (Diluted) | $-1.00 -257.1% | $-0.28 +75.2% | $-1.13 | — | — | — |
| Total Assets | $56.1M -44.6% | $101.3M -20.5% | $127.4M -26.8% | $174.0M -40.2% | $291.1M -73.2% | $1.08B |
| Operating Cash Flow | $-51.2M -116.9% | $-23.6M +50.5% | $-47.7M | — | — | — |
| Free Cash Flow | $-51.6M -112.0% | $-24.4M +49.1% | $-47.8M | — | — | — |
Get alerted when CNTB's score changes
Free account: watchlist tracking, the daily AI brief, and the AI screener.
Available Research
13F Pro tracks comprehensive data for Connect Biopharma Holdings Ltd including:
Top Institutional Holders of CNTB
Ikarian Capital, LLC
$10.8M4,538,534 sh683 Capital Management, LLC
$3.1M1,285,000 shBOOTHBAY FUND MANAGEMENT, LLC
$2.3M973,732 shBlackRock, Inc.
$2.1M871,653 shPERCEPTIVE ADVISORS LLC
$1.9M792,696 shADAR1 Capital Management, LLC
$1.7M700,000 shBML Capital Management, LLC
$1.4M573,287 shSILVERARC CAPITAL MANAGEMENT, LLC
$1.3M545,000 shRichmond Brothers, Inc.
$1.3M535,612 shKnott David M Jr
$1.1M444,862 sh
| Fund | Value | Shares |
|---|---|---|
| Ikarian Capital, LLC | $10.8M | 4,538,534 |
| 683 Capital Management, LLC | $3.1M | 1,285,000 |
| BOOTHBAY FUND MANAGEMENT, LLC | $2.3M | 973,732 |
| BlackRock, Inc. | $2.1M | 871,653 |
| PERCEPTIVE ADVISORS LLC | $1.9M | 792,696 |
| ADAR1 Capital Management, LLC | $1.7M | 700,000 |
| BML Capital Management, LLC | $1.4M | 573,287 |
| SILVERARC CAPITAL MANAGEMENT, LLC | $1.3M | 545,000 |
| Richmond Brothers, Inc. | $1.3M | 535,612 |
| Knott David M Jr | $1.1M | 444,862 |
More Healthcare Companies
View all Healthcare →Put CNTB on your watchlist
Track score changes the day Connect Biopharma Holdings Ltd files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.
Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).
Popular Research
Is CNTB a good stock to buy?
13F Pro's AI-powered analysis of Connect Biopharma Holdings Ltd (CNTB) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for CNTB are available on the CNTB stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing. CNTB is classified as a small company.
Which hedge funds own CNTB?
Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling CNTB. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Connect Biopharma Holdings Ltd's investment landscape.